Molecular basis for the antagonistic activity of an anti-CXCR4 antibody

References

• Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272:872–77; PMID:8629022; http://dx.doi.org/10.1126/science.272.5263.872
   PubMed Web of Science ®Google Scholar
• Bleul CC, Farzan M, Choe H, Parolin C, ClarkLewis I, Sodroski J, Springer TA. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996; 382:829–33; PMID:8752280; http://dx.doi.org/10.1038/382829a0
   PubMed Web of Science ®Google Scholar
• Loetscher M, Geiser T, O'Reilly T, Zwahlen R, Baggiolini M, Moser B. Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. J Biol Chem 1994; 269:232–37; PMID:8276799
   PubMed Web of Science ®Google Scholar
• Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393:595–99; PMID:9634238; http://dx.doi.org/10.1038/31269
   PubMed Web of Science ®Google Scholar
• Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, Kishimoto T, Bronson RT, Springer TA. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. PNAS USA 1998; 95:9448–53; PMID:9689100; http://dx.doi.org/10.1073/pnas.95.16.9448
   PubMed Web of Science ®Google Scholar
• McGrath KE, Koniski AD, Maltby KM, McGann JK, Palis J. Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4. Dev Biol 1999; 213:442–56; PMID:10479460; http://dx.doi.org/10.1006/dbio.1999.9405
   PubMed Web of Science ®Google Scholar
• Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H, Kishimoto T. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996; 382:635–38; PMID:8757135; http://dx.doi.org/10.1038/382635a0
   PubMed Web of Science ®Google Scholar
• Murphy PM. The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol 1994; 12:593–633; PMID:8011292; http://dx.doi.org/10.1146/annurev.iy.12.040194.003113
   PubMed Web of Science ®Google Scholar
• Doranz BJ, Berson JF, Rucker J. Doms RW. Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1). Immunol Res 1997; 16:15–28; PMID:9048206; http://dx.doi.org/10.1007/BF02786321
   PubMed Web of Science ®Google Scholar
• Nanki T, Hayashida K, El-Gabalawy HS, Suson S, Shi K, Girschick HJ, Yavuz S, Lipsky PE. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol 2000; 165:6590–98; PMID:11086103; http://dx.doi.org/10.4049/jimmunol.165.11.6590
   PubMed Web of Science ®Google Scholar
• Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410:50–56; PMID:11242036; http://dx.doi.org/10.1038/35065016
   PubMed Web of Science ®Google Scholar
• Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4:540–50; PMID:15229479; http://dx.doi.org/10.1038/nrc1388
   PubMed Web of Science ®Google Scholar
• Zlotnik A. New insights on the role of CXCR4 in cancer metastasis. J Pathol 2008; 215:211–13; PMID:18523970; http://dx.doi.org/10.1002/path.2350
   PubMed Web of Science ®Google Scholar
• Fulton AM. The chemokine receptors CXCR4 and CXCR3 in cancer. Curr Oncol Rep 2009; 11:125–31; PMID:19216844; http://dx.doi.org/10.1007/s11912-009-0019-1
   PubMed Web of Science ®Google Scholar
• Teicher BA. Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16:2927–31; PMID:20484021; http://dx.doi.org/10.1158/1078-0432.CCR-09-2329
   PubMed Web of Science ®Google Scholar
• Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004; 14:171–79; PMID:15246052; http://dx.doi.org/10.1016/j.semcancer.2003.10.003
   PubMed Web of Science ®Google Scholar
• Tamamura H, Fujii N. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Expert Opin. Ther. Targets 2005; 9:1267–82
   Google Scholar
• Patrussi L, Baldari CT. The CXCL12/CXCR4 axis as a therapeutic target in cancer and HIV-1 infection. Curr Med Chem 2011; 18:497–512; PMID:21143114; http://dx.doi.org/10.2174/092986711794480159
   PubMed Web of Science ®Google Scholar
• Weitzenfeld P, Ben-Baruch A. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Lett 2014; 352:36–53; PMID:24141062; http://dx.doi.org/10.1016/j.canlet.2013.10.006
   PubMed Web of Science ®Google Scholar
• Kuhne MR, Mulvey T, Belanger B, Chen S, Pan C, Chong C, Cao F, Niekro W, Kempe T, Henning KA, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res 2013; 19:357–66; PMID:23213054; http://dx.doi.org/10.1158/1078-0432.CCR-12-2333
   PubMed Web of Science ®Google Scholar
• Kamal A, Steiner P, Wang Y, Wetzel L, Mazzola A, Passino M, McDermott B, Huang K, Peng L, Rebelatto M, et al. (2013) AACR Meeting Abstracts abstract 5462.
   Google Scholar
• Schols D, Struyf S, Van Damme J, Este JA, Henson G, De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997; 186:1383–88; PMID:9334378; http://dx.doi.org/10.1084/jem.186.8.1383
   PubMed Web of Science ®Google Scholar
• De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003; 2:581–87; PMID:12815382; http://dx.doi.org/10.1038/nrd1134
   PubMed Web of Science ®Google Scholar
• Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998; 4:72–7; PMID:9427609; http://dx.doi.org/10.1038/nm0198-072
   PubMed Web of Science ®Google Scholar
• Matthys P, Hatse S, Vermeire K, Wuyts A, Bridger G, Henson GW, De Clercq E, Billiau A, Schols D. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol 2001; 167:4686–92; PMID:11591799; http://dx.doi.org/10.4049/jimmunol.167.8.4686
   PubMed Web of Science ®Google Scholar
• Lukacs NW, Berlin A, Schols D, Skerlj RT, Bridger GJ. AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am J Pathol 2002; 160:1353–60; PMID:11943720; http://dx.doi.org/10.1016/S0002-9440(10)62562-X
   PubMed Web of Science ®Google Scholar
• Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S, Hangoc G, Bridger GJ, Henson GW, Calandra G, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102:2728–30; PMID:12855591; http://dx.doi.org/10.1182/blood-2003-02-0663
   PubMed Web of Science ®Google Scholar
• Domanska UM, Timmer-Bosscha H, Nagengast WB, Oude Munnink TH, Kruizinga RC, Ananias HJ, Kliphuis NM, Huls G, De Vries EG, de Jong IJ, et al. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia 2012; 14:709–18; PMID:22952424; http://dx.doi.org/10.1593/neo.12324
   PubMed Web of Science ®Google Scholar
• De Clercq E. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacol Ther 2010; 128:509–18; PMID:20826182; http://dx.doi.org/10.1016/j.pharmthera.2010.08.009
   PubMed Web of Science ®Google Scholar
• Kessans MR, Gatesman ML, Kockler DR. Plerixafor: a peripheral blood stem cell mobilizer. Pharmacotherapy 2010; 30:485–92; PMID:20411999; http://dx.doi.org/10.1592/phco.30.5.485
   PubMed Web of Science ®Google Scholar
• Choi HY, Yong CS, Yoo BK. Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma. Ann Pharmacother 2010; 44:117–26; PMID:20009003; http://dx.doi.org/10.1345/aph.1M380
   PubMed Web of Science ®Google Scholar
• Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H, Yoshida N, Waki M, Matsumoto A, Yoshie O, et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 1997; 186:1389–93; PMID:9334379; http://dx.doi.org/10.1084/jem.186.8.1389
   PubMed Web of Science ®Google Scholar
• Arakaki R, Tamamura H, Premanathan M, Kanbara K, Ramanan S, Mochizuki K, Baba M, Fujii N, Nakashima H. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol 1999; 73:1719–23; PMID:9882387
   PubMed Web of Science ®Google Scholar
• Tamamura H, Hori A, Kanzaki N, Hiramatsu K, Mizumoto M, Nakashima H, Yamamoto N, Otaka A, Fujii N. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett 2003; 550:79–83; PMID:12935890; http://dx.doi.org/10.1016/S0014-5793(03)00824-X
   PubMed Web of Science ®Google Scholar
• Tamamura H, Hiramatsu K, Mizumoto M, Ueda S, Kusano S, Terakubo S, Akamatsu M, Yamamoto N, Trent JO, Wang ZP, et al. Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonists. Org Biomol Chem 2003; 1:3663–69; PMID:14649897; http://dx.doi.org/10.1039/b306613b
   PubMed Web of Science ®Google Scholar
• Tamamura H, Esaka A, Ogawa T, Araki T, Ueda S, Wang Z, Trent JO, Tsutsumi H, Masuno H, Nakashima H, et al. Structure-activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffolds. Org Biomol Chem 2005; 3:4392–94; PMID:16327900; http://dx.doi.org/10.1039/b513145f
   PubMed Web of Science ®Google Scholar
• Rosenkilde MM, Gerlach LO, Jakobsen JS, Skerlj RT, Bridger GJ, Schwartz TW. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor. J Biol Chem 2004; 279:3033–41; PMID:14585837; http://dx.doi.org/10.1074/jbc.M309546200
   PubMed Web of Science ®Google Scholar
• Tamamura H, Xu Y, Hattori T, Zhang X, Arakaki R, Kanbara K, Omagari A, Otaka A, Ibuka T, Yamamoto N, et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun 1998; 253:877–82; PMID:9918823; http://dx.doi.org/10.1006/bbrc.1998.9871
   PubMed Web of Science ®Google Scholar
• Kawatkar SP, Yan M, Gevariya H, Lim MY, Eisold S, Zhu X, Huang Z, An J. Computational analysis of the structural mechanism of inhibition of chemokine receptor CXCR4 by small molecule antagonists. Exp Biol Med (Maywood) 2011; 236:844–50; PMID:21697335; http://dx.doi.org/10.1258/ebm.2011.010345
   PubMed Web of Science ®Google Scholar
• Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, Bi FC, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010; 330:1066–71; PMID:20929726; http://dx.doi.org/10.1126/science.1194396
   PubMed Web of Science ®Google Scholar
• Yoshikawa Y, Kobayashi K, Oishi S, Fujii N, Furuya T. Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions. Bioorg Med Chem Lett 2012; 22:2146–50; PMID:22365757; http://dx.doi.org/10.1016/j.bmcl.2012.01.134
   PubMed Web of Science ®Google Scholar
• Brelot A, Heveker N, Montes M, Alizon M. Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities. J Biol Chem 2000; 275:23736–44; PMID:10825158; http://dx.doi.org/10.1074/jbc.M000776200
   PubMed Web of Science ®Google Scholar
• Brelot A, Heveker N, Adema K, Hosie MJ, Willett B, Alizon M. Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. J Virol 1999; 73:2576–86; PMID:10074102
   PubMed Web of Science ®Google Scholar
• Bertolini F, Dell'Agnola C, Mancuso P, Rabascio C, Burlini A, Monestiroli S, Gobbi A, Pruneri G, Martinelli G. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res 2002; 62:3106–12; PMID:12036921
   PubMed Web of Science ®Google Scholar
• Engl T, Relja B, Marian D, Blumenberg C, Muller I, Beecken WD, Jones J, Ringel EM, Bereiter-Hahn J, Jonas D, et al. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia 2006; 8:290–301; PMID:16756721; http://dx.doi.org/10.1593/neo.05694
   PubMed Web of Science ®Google Scholar
• Gelmini S, Mangoni M, Castiglione F, Beltrami C, Pieralli A, Andersson KL, Fambrini M, Taddei GL, Serio M, Orlando C. The CXCR4/CXCL12 axis in endometrial cancer. Clin Exp Metastasis 2009; 26:261–68; http://dx.doi.org/10.1007/s10585-009-9240-4
   PubMed Web of Science ®Google Scholar
• Cheng Z, Zhou S, Wang X, Xie F, Wu H, Liu G, Wang Q, Chen Y, Hu Y, Lu B, et al. Characterization and application of two novel monoclonal antibodies against human CXCR4: cell proliferation and migration regulation for glioma cell line in vitro by CXCR4/SDF-1alpha signal. Hybridoma (Larchmt) 2009; 8:33–41; http://dx.doi.org/10.1089/hyb.2008.0069
   Google Scholar
• Tanaka R, Yoshida A, Murakami T, Baba E, Lichtenfeld J, Omori T, Kimura T, Tsurutani N, Fujii N, Wang ZX, et al. Unique monoclonal antibody recognizing the third extracellular loop of CXCR4 induces lymphocyte agglutination and enhances human immunodeficiency virus type 1-mediated syncytium formation and productive infection. J Virol 2001; 75:11534–43; PMID:11689635; http://dx.doi.org/10.1128/JVI.75.23.11534-11543.2001
   PubMed Web of Science ®Google Scholar
• Carnec X, Quan L, Olson WC, Hazan U, Dragic T. Anti-CXCR4 monoclonal antibodies recognizing overlapping epitopes differ significantly in their ability to inhibit entry of human immunodeficiency virus type 1. J Virol 2005; 79:1930–33; PMID:15650218; http://dx.doi.org/10.1128/JVI.79.3.1930-1933.2005
   PubMed Web of Science ®Google Scholar
• Xu C, Sui J, Tao H, Zhu Q, Marasco WA. Human anti-CXCR4 antibodies undergo VH replacement, exhibit functional V-region sulfation, and define CXCR4 antigenic heterogeneity. J Immunol 2007; 179:2408–18; PMID:17675502; http://dx.doi.org/10.4049/jimmunol.179.4.2408
   PubMed Web of Science ®Google Scholar
• Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of proteins of immunological interest. U.S. Public Health Service, National Institutes of Health, Washington, DC 1997.
   Google Scholar
• Zemlin M, Klinger M, Link J, Zemlin C, Bauer K, Engler JA, Schroeder HW, Kirkham PM. Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures. J Mol Biol 2003; 334:733–49; PMID:14636599; http://dx.doi.org/10.1016/j.jmb.2003.10.007
   PubMed Web of Science ®Google Scholar
• Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, Sheriff S, Padlan EA, Davies D, Tulip WR, et al. Conformations of immunoglobulin hypervariable regions. Nature 1989; 342:877–83; PMID:2687698; http://dx.doi.org/10.1038/342877a0
   PubMed Web of Science ®Google Scholar
• Chothia C, Lesk AM, Gherardi E, Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G. Structural repertoire of the human VH segments. J Mol Biol 1992; 227:799–817; PMID:1404389; http://dx.doi.org/10.1016/0022-2836(92)90224-8
   PubMed Web of Science ®Google Scholar
• Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 1997; 273:927–48; PMID:9367782; http://dx.doi.org/10.1006/jmbi.1997.1354
   PubMed Web of Science ®Google Scholar
• Foote J, Winter G. Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops. J Mol Biol 1992; 224:487–99; PMID:1560463; http://dx.doi.org/10.1016/0022-2836(92)91010-M
   PubMed Web of Science ®Google Scholar
• Forster R, Kremmer E, Schubel A, Breitfeld D, Kleinschmidt A, Nerl C, Bernhardt G, Lipp M. Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation. J Immunol 1998; 160:1522–31; PMID:9570576
   PubMed Web of Science ®Google Scholar
• Gerlach LO, Skerlj RT, Bridger GJ, Schwartz TW. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 2001; 276:14153–60; PMID:11154697
   PubMed Web of Science ®Google Scholar
• Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold M, Sunshine MJ, Littman DR, Kuo CJ, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006; 203:2201–13; PMID:16940167; http://dx.doi.org/10.1084/jem.20052144
   PubMed Web of Science ®Google Scholar
• Almagro JC, Beavers MP, Hernandez-Guzman F, Maier J, Shaulsky J, Butenhof K, Labute P, Thorsteinson N, Kelly K, Teplyakov A, et al. Antibody modeling assessment. Proteins 2011; 79:3050–66; PMID:21935986; http://dx.doi.org/10.1002/prot.23130
   PubMed Web of Science ®Google Scholar
• Shirai H, Kidera A, Nakamura H. H3-rules: identification of CDR-H3 structures in antibodies. FEBS Lett 1999; 455:188–97; PMID:10428499; http://dx.doi.org/10.1016/S0014-5793(99)00821-2
   PubMed Web of Science ®Google Scholar
• Kuroda D, Shirai H, Kobori M, Nakamura H. Structural classification of CDR-H3 revisited: a lesson in antibody modeling. Proteins 2008; 73:608–20; PMID:18473362; http://dx.doi.org/10.1002/prot.22087
   PubMed Web of Science ®Google Scholar
• Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. Charmm - a Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J Comp Chem 1983; 4:187–217; http://dx.doi.org/10.1002/jcc.540040211
   Web of Science ®Google Scholar
• Brooks BR, Brooks CL, Mackerell AD, Nilsson L, Petrella RJ, Roux B, Won Y, Archontis G, Bartels C, Boresch S, et al. CHARMM: The Biomolecular Simulation Program. J Comp Chem 2009; 30:1545–1614; http://dx.doi.org/10.1002/jcc.21287
   PubMed Web of Science ®Google Scholar
• Chen R, Li L, Weng Z. ZDOCK: An Initial-stage Protein-Docking algorithm. Proteins 2003; 52: 80–7; PMID:12784371; http://dx.doi.org/10.1002/prot.10389
   PubMed Web of Science ®Google Scholar
• Li L, Chen R, Weng Z. RDOCK: refinement of rigid-body protein docking predictions. Proteins 2003; 53:693–707; PMID:14579360; http://dx.doi.org/10.1002/prot.10460
   PubMed Web of Science ®Google Scholar
• Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Arenzana-Seisdedos F, Virelizier JL, Baggiolini M, Sykes BD, Clark-Lewis I. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 1997; 16:6996–7007; PMID:9384579; http://dx.doi.org/10.1093/emboj/16.23.6996
   PubMed Web of Science ®Google Scholar
• Dealwis C, Fernandez EJ, Thompson DA, Simon RJ, Siani MA, Lolis E. Crystal structure of chemically synthesized ; N33A stromal cell-derived factor 1alpha, a potent ligand for the HIV-1 "fusin" coreceptor. PNAS USA 1998; 95:6941–46; PMID:9618518; http://dx.doi.org/10.1073/pnas.95.12.6941
   PubMed Web of Science ®Google Scholar
• Gupta SK, Pillarisetti K, Thomas RA, Aiyar N. Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists. Immunol Lett 2001; 78:29–34; PMID:11470148; http://dx.doi.org/10.1016/S0165-2478(01)00228-0
   PubMed Web of Science ®Google Scholar
• Clark-Lewis I, Kim KS, Rajarathnam K, Gong JH, Dewald B, Moser B, Baggiolini M, Sykes BD. Structure-activity relationships of chemokines. J Leukoc Biol 1995; 57:703–11; PMID:7759949
   PubMed Web of Science ®Google Scholar
• Wells TN, Power CA, Lusti-Narasimhan M, Hoogewerf AJ, Cooke RM, Chung CW, Peitsch MC, Proudfoot AE. Selectivity and antagonism of chemokine receptors. J Leukoc Biol 1996; 59:53–60; PMID:8558067
   PubMed Web of Science ®Google Scholar
• Kufareva I, Stephens BS, Holden LG, Qin L, Zhao C, Kawamura T, Abagyan R, Handel TM. Stoichiometry and geometry of the CXC chemokine receptor 4 complex with CXC ligand 12: Molecular modeling and experimental validation. PNAS 2014; 111:E5363–E5372; PMID:25468967; http://dx.doi.org/10.1073/pnas.1417037111
   PubMedGoogle Scholar
• Qin L, Kufareva I, Holden LG, Wang C, Zheng Y, Zhao C, Fenalti G, Wu H, Han GW, Cherezov V, et al. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine. Science 2015; 347:1117–22; PMID:25612609; http://dx.doi.org/10.1126/science.1261064
   PubMed Web of Science ®Google Scholar
• Jähnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, De Vrieze S, Serruys B, Ulrichts H, Vandevelde W, et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. PNAS 2010; 107:20565–70; http://dx.doi.org/10.1073/pnas.1012865107
   PubMed Web of Science ®Google Scholar
• BouHamdan M, Strayer DS, Wei D, Mukhtar M, Duan LX, Hoxie J, Pomerantz RJ. Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4. Gene Ther 2001; 8:408–18; PMID:11313818; http://dx.doi.org/10.1038/sj.gt.3301411
   PubMed Web of Science ®Google Scholar
• Baribaud F, Edwards TG, Sharron M, Brelot A, Heveker N, Price K, Mortari F, Alizon M, Tsang M, Doms RW. Antigenically distinct conformations of CXCR4. J Virol 2001; 75:8957–67; PMID:11533159; http://dx.doi.org/10.1128/JVI.75.19.8957-8967.2001
   PubMed Web of Science ®Google Scholar
• Huskens D, Princen K, Schreiber M, Schols D. The role of N-glycosylation sites on the CXCR4 receptor for CXCL-12 binding and signaling and X4 HIV-1 viral infectivity. Virology 2007; 363:280–7; PMID:17331556; http://dx.doi.org/10.1016/j.virol.2007.01.031
   PubMed Web of Science ®Google Scholar
• Chabot DJ, Chen H, Dimitrov DS, Broder CC. N-Linked Glycosylation of CXCR4 Masks Coreceptor Function for CCR5-Dependent Human Immunodeficiency Virus Type 1 Isolates. J Virol 2000; 74:4404–13; PMID:10756055; http://dx.doi.org/10.1128/JVI.74.9.4404-4413.2000
   PubMed Web of Science ®Google Scholar
• Milligan G. Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol Pharmacol 2003; 64:1271–6; PMID:14645655; http://dx.doi.org/10.1124/mol.64.6.1271
   PubMed Web of Science ®Google Scholar
• Dimasi N, Gao C, Fleming R, Woods RM, Yao XT, Shirinian L, Kiener PA, Wu H. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol 2009; 393:672–92; PMID:19699208; http://dx.doi.org/10.1016/j.jmb.2009.08.032
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res 2000; 28:235–42; http://dx.doi.org/10.1093/nar/28.1.235
   PubMed Web of Science ®Google Scholar